There is an issue with this study and the authors address this problem at the end. This is a retrospective study, covering patient data from March 10th through May 2nd, 2020. This means this data is not from a randomized, double blind, placebo controlled trial. That doesn’t make the data incorrect, but it typically means the drug in question needs to. E tested in a properly controlled trial. The other trials in which HCQ demonstrated no efficacy were controlled/placebo/blinded, the most recent being the trial where HCQ showed no statistically difference vs placebo in preventing COVID19 infection in at risk patients. The data looks promising and I’m assuming a proper clinical trial to assess the drug in the hospital setting will commence soon.

“Dr. Zervos also pointed out, as does the paper, that the study results should be interpreted with some caution, should not be applied to patients treated outside of hospital settings and require further confirmation in prospective, randomized controlled trials that rigorously evaluate the safety and efficacy of hydroxychloroquine therapy for COVID-19.”